Skip to main content

Table 2 PrEP and HIV related knowledge, cognition, and behavior (N = 689)

From: Low willingness to pay for pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in China

Items

N %

Mean ± SD

Willingness to pay for PrEP

 Amount willing to pay for PrEP per month (USD)

  0

97

14.1

   < 14

66

9.6

  14–28

139

20.2

  29–57

118

17.1

  58–84

82

11.9

  85–113

33

4.8

  114–141

50

7.3

  142–282

57

8.3

   ≥ 283

47

6.8

 Percentage (of personal income) of willing to pay for PrEP

  0

97

14.1

   < 5%

193

28.0

  6–10%

117

17.0

  11–25%

154

22.4

   > 25%

128

18.6

HIV-related characteristics

 Perceived risk of HIV infection (range: 1–5)

2.36 ± 1.09

 Perceived risk of STI infection (range: 1–5)

2.22 ± 1.10

 HIV literacy score a (range: 0–12)

9.25 ± 1.98

 Sexual behaviors in the past month

  Inconsistent condom use (Yes)

199

28.9

  Engage in multiple sex partnership (Yes)

212

30.8

 HIV status communication with partners

HIV disclosure scale to sexual partnersb (range: 2–10)

6.95 ± 2.69

PrEP-related cognition

 PrEP awareness

  Awareness of daily oral PrEP (Yes)

225

32.7

  Awareness of on-demand PrEP (Yes)

205

29.8

  Awareness of long injecting PrEP (Yes)

43

6.2

PrEP awareness scalec(range: 0–3)

0.69 ± 0.80

 PrEP acceptability

  Willingness to use daily oral PrEP (very likely/likely)

421

61.1

  Willingness to use on-demand PrEP (very likely/likely)

540

78.4

  Willingness to use LAI-PrEP (very likely/likely)

439

63.7

PrEP acceptability scaled(range: 3–15)

11.44 ± 3.41

 Perceived PrEP adherence

  Perceived adherence to daily oral PrEP (very high/high)

487

70.7

  Perceived adherence to on-demand PrEP (very high/high)

580

84.2

  Perceived adherence to LAI-PrEP (very high/high)

490

71.1

Perceived PrEP adherence scalee(range: 3–15)

12.27 ± 3.23

 Perceived PrEP benefit in reducing condom use (range: 1–5)

2.38 ± 1.55

  1. STI sexually transmitted infection, PrEP Pre-exposure prophylaxis, LAI-PrEP Long-acting Injectable PrEP;
  2. aThe Cronbach’s alpha coefficient was 0.626, and 4 factors explained 53.1% of the total variance;
  3. bThe Cronbach’s alpha coefficient was 0.786, and 1 factor explained 82.4% of the total variance;
  4. cThe Cronbach’s alpha coefficient was 0.356, and 1 factor explained 45.2% of the total variance;
  5. dThe Cronbach’s alpha coefficient was 0.820, and 1 factor explained 73.9% of the total variance;
  6. eThe Cronbach’s alpha coefficient was 0.832, and 1 factor explained 75.2% of the total variance;
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us